Shandong Xinhua Pharmaceutical Company Limited (referred to as Xinhua Pharmaceutical, stock code: 000756) announced that it has received a Drug Registration Certificate from the National Medical Products Administration for its Glucosamine Sulfate Capsules.

According to the announcement dated 9 February 2026, Glucosamine Sulfate Capsules fall under Class 4 chemicals and will be managed as Category A non-prescription drugs. The product specifications range from 0.25g (based on glucosamine sulfate content) to 0.314g (based on glucosamine sulfate and sodium chloride content). It is primarily indicated for the treatment of primary and secondary osteoarthritis, and it is listed as a Category B product in the “National Drug Catalogue for Basic Medical Insurance, Work Related-Injury Insurance, and Maternity Insurance (2025).” The company noted that sales of similar products in China’s public medical institutions reached approximately RMB 850 million in 2024.

The announcement also highlighted that obtaining the certificate enhances Xinhua Pharmaceutical’s product portfolio and comprehensive competitiveness. However, the company stated that its pharmaceutical sales may be influenced by changes in industry policies, market conditions, and other factors, advising investors to consider such uncertainties carefully.